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Background: Thyroid cancer, as with other types of cancer, is dependent on angiogenesis for its continued growth
and development. Interestingly, estrogen has been shown to contribute to thyroid cancer aggressiveness in vitro,
which is in full support of the observed increased incidence of thyroid cancer in women over men. Provided that
estrogen has been observed to contribute to increased angiogenesis of estrogen responsive breast cancer, it is
conceivable to speculate that estrogen also contributes to angiogenesis of estrogen responsive thyroid cancer.
Methods: In this study, three human thyroid cancer cells (B-CPAP, CGTH-W-1, ML-1) were treated with estrogen
alone or estrogen and anti-estrogens (fulvestrant and 3,3′-diindolylmethane, a natural dietary compound) for
24 hours. The cell culture media was then added to human umbilical vein endothelial cell (HUVECs) and assayed for
angiogenesis associated events. Vascular endothelial growth factor (VEGF) levels were also quantified in the
conditioned media so as to evaluate if it is a key player involved in these observations.
Results: Conditioned medium from estrogen treated thyroid cancer cells enhanced phenotypical changes
(proliferation, migration and tubulogenesis) of endothelial cells typically observed during angiogenesis. These
phenotypic changes observed in HUVECs were determined to be modulated by estrogen induced secretion of
VEGF by the cancer cells. Lastly, we show that VEGF secretion was inhibited by the anti-estrogens, fulvestrant and
3,3′-diindolylmethane, which resulted in diminished angiogenesis associated events in HUVECs.
Conclusion: Our data establishes estrogen as being a key regulator of VEGF secretion/expression in thyroid cells
which enhances the process of angiogenesis in thyroid cancer. These findings also suggest the clinical utility of anti-
estrogens as anti-angiogenic compounds to be used as a therapeutic means to treat thyroid cancer. We also
observed that 3,3′-diindolylmethane is a promising naturally occurring anti-estrogen which can be used as a part of
therapeutic regimen to treat thyroid cancer.
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The thyroid gland is a highly vascularized organ with
increased vascularity observed in thyroid diseases, such as
Graves’ disease, goiter and cancer, due to increased meta-
bolic demand required for abnormal growth [1]. Common
characteristics observed during this increased vascularity
are enhanced endothelial cell proliferation, blood capillary
enlargement, and ultimately the sprouting of new blood
vessels from preexisting capillaries [2]. All of these pheno-
typic changes that occur are all aimed at sustaining thyroid* Correspondence: raj_tiwari@nymc.edu
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reproduction in any medium, provided the orgrowth and development as well as the potential of well dif-
ferentiated thyroid carcinoma cells to metastasize to the re-
gional lymph nodes, which is negatively correlated with
poor prognosis and disease-free survival in patients [3,4].
This phenomenon of increased vasculature, also known as
angiogenesis, is a critical and tightly regulated event that is
controlled by the interplay between various cytokines and
chemokines [2].
Angiogenesis involves the coordinated and directed
proliferation and migration of endothelial cells, remodel-
ing of the extracellular matrix, induction of new sprouts
or tubes, anastomoses of newly formed and preexisting
vessels, and basement membrane formation, in responsetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[2,5]. Cancer cells are proposed to mediate angiogenesis
by secreting such growth factors that will bind to the re-
spective receptors present on the endothelial cells result-
ing in endothelial cell migration, proliferation and
tubulogenesis. These growth factors are termed as pro-
angiogenic factors and include transforming growth fac-
tor-α (TGF-α), angiogenin, vascular permeability growth
factor (VPF) and vascular endothelial growth factor
(VEGF) [6]. Production of these factors causes a con-
comitant increase in vascularization thus leading to rapid
tumor growth and metastasis. Of all the above men-
tioned factors involved in angiogenesis, many studies
demonstrate that VEGF is a critical mediator [6-8].
VEGF is a secreted homodimeric glycoprotein that acts
as a chemoattractant and mitogenic factor for endothe-
lial cells [8,9]. There are four major members of the
VEGF family, VEGF-A, -B, -C and –D with VEGF-A
being the predominant form and having at least six iso-
forms produced through alternative splicing [10,11]. All
VEGFs have differential tissue expression and bind to
their tyrosine kinase cell membrane receptors, VEGF-re-
ceptor (VEGFR) -1 (also called Flt-1), VEGFR-2 (also
called Flk/KDR), and VEGFR-3 (also called Flt-4) of
which endothelial cells express VEGFR-1 and VEFGR-2
[12]. VEGF has been repeatedly shown as a significant
component involved in regulation of thyroid angiogen-
esis with disturbances in intrathyroid VEGF expression
leading to several thyroid pathologies, including tumor
and goiter [1,13].
The expression of VEGF has been shown to be modu-
lated by steroid hormones such as estrogens in breast can-
cer [14,15]. Many in vitro and in vivo studies
demonstrate that estrogen and other growth factors pro-
mote angiogenesis in endothelial cells via the estrogen
receptor (ER) and that inhibition of ER regulates the
intracellular balance of pro and anti-angiogenic factors
[16]. Estrogen-ER binding also induces endothelial cell
proliferation and migration opening the possibility of
the use of ER competitors as possible antiangiogenic
agents. Our group has previously demonstrated an estrogen
induced enhanced expression of VEGF in vivo, thus, partici-
pating in neo-vascularization of estrogen responsive breast
tumor tissues [15]. In addition, we have recently shown that
estrogen enhances thyroid cancer cell proliferation and me-
tastasis associated events such as migration, adhesion and
invasion, at least partly by induction and activation of essen-
tial proteolytic enzymes, mainly matrix metalloproteinases-
2 (MMP-2) and MMP-9 [17]. The MMP system plays an
important role degradation of extracellular matrix, thus not
only aiding in tumor cell invasion and metastases, but also
in endothelial cell migration and angiogenesis [18]. These
observations along with literature suggest that estrogen is
an important pro-angiogenic factor that regulatesangiogenesis in hormone responsive tissues by affect-
ing the balance of pro- and anti-angiogenic factors,
but the effect of estrogen in angiogenesis of thyroid
cancer is still not fully elucidated.
The rationale of this study was to determine the con-
tribution of estrogen on angiogenesis of thyroid cancer
and in order to do so, in vitro experiments were initiated
using human thyroid cancer cells and human umbilical
vein endothelial cell (HUVECs). We demonstrate that es-
trogen treated thyroid cancer cells secrete factors that
promote phenotypic changes in HUVECs leading to
enhanced migration, proliferation and tubulogenesis of
endothelial cells. We also observed that these phenotypic
changes in HUVECs are induced by the estrogen
mediated secretion of the soluble ligand (VEGF) by can-
cer cells. We also investigated the effects of the anti-es-
trogenic compound 3,3’-diindolylmethane (DIM) on
angiogenesis of thyroid cancer cells. DIM is a promising
naturally available bioactive compound which can be
used as an anticarcinogenic agent and anti-estrogen as it
provides a safer and predictable response and has been
shown to affect estrogen responsive tissues such as
breast [17,19,20]. As regards to cancer prevention, sev-
eral studies have demonstrated that the consumption of
certain foods such as cruciferous vegetables have an in-
verse relationship with cancer risk. Recently, our group
has discovered that DIM modulates the estrogen metab-
olism in thyroid proliferative disease patients, generating
metabolites with anti-estrogenic activity, thus resulting
in an increase in the ratio of 2-hydroxyestrones (C-2) to
16α-hydroxyestrone (C-16) [21]. We have recently
demonstrated the anti-estrogenic effects of DIM on
in vitro thyroid cancer cell proliferation, adhesion, inva-
sion and migration [17]. These observations suggests
that DIM may be a promising naturally available bio-
active compound which can be used as an anticarcino-
genic agent and anti-estrogen as it provides a safer and
predictable response and has been shown to affect estro-
gen responsive tissues such as breast. In the present
communication, we observe that estrogen induced angio-
genesis is targeted by DIM by downregulating the bio-
availability of proangiogenic factor VEGF as evidenced
by reduced angiogenesis of HUVEC by DIM treated thy-
roid cancer cell conditioned medium. Our observations
suggest that estrogen is a mediator of angiogenesis as it
that might activate the formation of a paracrine loop be-
tween endothelial cells and thyroid cancer cells, which is
targeted by DIM.
Methods
Cell culture Three thyroid cell lines were used in this
study, BCPAP (human papillary thyroid cancer cell line),
CGTHW-1 (human follicular thyroid cancer cell line)
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cancer cells were purchased from DSMZ, Braunschweig,
Germany. BCPAP and CGTHW-1 were cultured in
RPMI-1640 (Mediatech, Herndon, VA) supplemented
with 10% fetal bovine serum (FBS) (Atlanta Biologicals,
Atlanta, GA), penicillin 10,000 IU/ml, streptomycin
10,000 μg/ml (Mediatech) and 2 mM L-glutamine
(Mediatech). ML-1 was grown in DMEM (Mediatech)
supplemented with 10% FBS, penicillin 10,000 IU/ml,
streptomycin 10,000 μg/ml and 2 mM L-glutamine.
Human Umblical Vein Endothelial Cells (HUVECs)
(ATCC, Manassas, VA) were grown in FK-12 supplemen-
ted with 10% fetal bovine serum (FBS), 50 IU/ml penicil-
lin, 50 μg/ml streptomycin, ECGS and heparin and were
cultured only till passage 40.
Conditioned medium generation Thyroid cells were
seeded at a density of 5X105 cells per well in 6-well cul-
ture dishes and allowed to adhere overnight after which
they were then switched to serum free medium and
incubated with 10-8 M estrogen (E2) (Sigma Chemical
Company, St. Louis, MO)± 10-6 M fulvestrant (Sigma
Chemical Co.)± 25 μM DIM or left untreated for
24 hours. DIM is kindly provided by Dr. Michael
Zeligs (BioResponse, Boulder, Colorado) for all the
experiments. The ‘conditioned medium’ was then har-
vested and centrifuged to remove any debris and aliquots
were stored at −80°C until used.
HUVEC migration Migration of HUVEC cells is crucial
for angiogenesis and the ability of thyroid conditioned
medium to modulate this event was examined using a
modified Boyden chamber technique. Transwell Control
Inserts with 3-μm pore membrane filters were used for
HUVEC migration assay. HUVECs were harvested by
trypsinization and 1x104 cells were seeded in the upper
chamber in 100 μl of media containing 1% FBS. The
lower chamber contained 600 μl of thyroid cancer cell
conditioned medium (thyroid cancer cells treated with ±
10-8 M E2 ± 10
-6 M fulvestrant ± 25 μM DIM for
24 hours) supplemented with 1% FBS. After 6 hours of
incubation, the non migrating cells were removed from
the upper surface of the membrane by gently scrubbing
using cotton tipped swab. Migrated cells on the lower
surface of the membrane were then fixed using methanol
and stained using 1% toluidine blue 1% borax stain fol-
lowed by two washes with distilled water. Inserts were
then allowed to airdry and counted in 10X field. Data are
expressed as numbers of migrated cells per 10X field
micrograph for each sample well and normalized to cell
counts obtained from the untreated control.
HUVEC proliferation assay To evaluate the biological
activity of conditioned medium obtained from thyroidcancer cells, a HUVEC proliferation assay was carried
out. Fresh conditioned medium was obtained from thy-
roid cancer cells treated with ± 10-8 M E2 ± 10
-6 M fulves-
trant ± 25 μM DIM for 24 hours. HUVECs were
harvested and seeded at a density of 1x104 cells per well
in 6-well culture dishes in triplicate repeats and allowed
to adhere overnight. After approximately 16–18 hours,
HUVECs were washed with serum free FK-12 and
HUVEC growth medium was changed to various thyroid
conditioned medium. After 24 hours of incubating
HUVECs in thyroid cancer cell conditioned medium,
HUVECs were harvested and stained using a 0.4% trypan
blue solution (Sigma Chemical Co.). The number of vi-
able (unstained) and dead (stained) cells was counted
and the effect of thyroid cancer cell conditioned medium
on HUVEC growth was calculated.
HUVEC tubulogenesis A matrigel tube formation assay,
known as tubulogenesis, was performed to assess the
ability of HUVECs to form endothelial cell vascular
structures or tubules which is implicated in being a very
crucial event for new vessel formation (angiogenesis). In-
dividual wells were coated with 100 μl of growth factor
reduced matrigel in a 96-well plate and allowed to
polymerize at 37°C for 1 hour. After polymerization,
1x104 HUVECs were resuspended in 100 μl thyroid can-
cer cells conditioned medium (thyroid cancer cells trea-
ted with ± 10-8 M E2 ± 10
-6 M fulvestrant ± 25 μM DIM
for 24 hours) were added to each well in triplicates. Cells
were inspected every three hours for tubule formation
and pictures were taken using light microscope at 5X.
VEGF ELISA The RayBioW Human VEGF ELISA (En-
zyme-Linked Immunosorbent Assay) kit (RayBiotech,
Inc., Norcross GA) was used for quantitative measure-
ment of VEGF secreted in the thyroid cancer cell condi-
tioned medium. Manufacturer’s instructions were
followed for detection of VEGF in thyroid cancer cell
conditioned medium. The mean absorbance for each set
of standards and samples was calculated and standard
curve was plotted with standards concentration on the
x-axis and absorbance in the y-axis. Based on the stand-
ard curve, VEGF concentration in pg/ml was calculated.
Neutralizing VEGF activity assay To confirm the activ-
ity of VEGF in angiogenesis associated events of thyroid
cancer cells, anti-human VEGF neutralizing antibody
(R&D Systems, Inc., Minneapolis, MN) was used to
neutralize VEGF bioactivity. Briefly, conditioned medium
was generated by treating thyroid cancer cells for
24 hours with estrogen and/or fulvestrant as described
earlier and stored at −80°C. Before the experiments, the
conditioned media was incubated with 1 μg of anti-
human VEGF neutralizing antibody per mL of the
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tioned media with or without the VEGF neutralizing
antibody was then used for tubulogenesis, proliferation
and migration of HUVECs as described in the earlier
section. This was to confirm that the angiogenesis asso-
ciated events observed with conditioned medium of thy-
roid cancer cells is related to the enhanced VEGF
secretion with estrogen treatments.
Western Blot analysis Cells were harvested using 0.25%
trypsin (Mediatech), washed with PBS, and lysed
(1 × 106/100 μL of lysis buffer) using the radioimmuno-
precipitation assay (RIPA) buffer [50 mM Tris–HCl (pH
7.4), 150 mM NaCl, 0.2% sodium deoxycholate, 0.1%
SDS, 0.5% NP40, 1 μM Pefabloc] and incubated on ice
for 30 minutes with intermittent vortexing. The lysates
were centrifuged at 14,000 rpm for 30 min at 4°C and
supernatant were collected. Cell lysates (20 μg protein)
were subjected to 12% SDS–PAGE under reducing con-
ditions (presence of β-mercaptoethanol) as described
earlier [17]. Briefly, the proteins were transferred to
Immobilon-P membranes at 220 mA for 2 h and mem-
branes were blocked with 4% dried milk in TBST
[200 mM Tris–HCl, pH 7.4, 150 mM NaCl, and 0.01%
Tween-20 added fresh/liter of 1×TBS (TBST)] for at
least 2–3 h on a shaker at room temperature. Subse-
quently, the membranes were incubated overnight at 4°C
with either VEGF (Santa Cruz Biotechnology, Santa
Cruz, CA) antibody or actin (Santa Cruz Biotechnology)
in TBST. Membranes were washed three times with
TBST and incubated with the respective horseradish per-
oxidase (HRP) conjugated secondary antibody, for
2 hours at room temperature in TBST containing 2%
milk. After four washes with TBS-T and one wash with
TBS, membranes were developed by ECL substrate
(Pierce Rockford, IL) and detected on Denville autoradi-
ography films.
Statistical Calculation Experiments presented here rep-
resent means of two to four replicates with statistical sig-
nificance determined using a paired Student’s t test and
one-way ANOVA followed by Tukey’s multiple compari-
son tests. The probability (‘p’ value) ≤ 0.05 was used to
reject the null hypothesis in all the experiments.
Results
Estrogen treated thyroid cancer cells enhance migration
of endothelial cells
In order to investigate the pro-angiogenic effects of es-
trogen in TPD, we first evaluated HUVEC migratory
function using a modified Boyden chamber technique.
HUVECs were cultured in transwell inserts with condi-
tioned media from thyroid cancer cells treated with es-
trogen ± fulvestrant in the lower chamber. We observedthat the migration of HUVECs to estrogen treated thy-
roid cancer cell conditioned medium was significantly
higher than that of untreated controls (Figure 1A). This
increase with estrogen treatment was approximately 45%
for B-CPAP conditioned medium, 41% for CGTH-W-1
conditioned medium and 46% for ML-1 thyroid cancer
cell conditioned medium. More interestingly, this estro-
gen enhanced increase in migration of HUVECs was
abrogated in the presence of fulvestrant. This decrease in
migration with fulvestrant and estrogen treated thyroid
cancer cell conditioned medium was 8-16% of untreated
cells and was cell line dependent. The fact that thyroid
cancer cell conditioned medium, even untreated thyroid
cancer cell conditioned medium, contains chemoattrac-
tants for endothelial cells has interesting implications
with respect to thyroid cancer and how it is capable of
initiating the event of its own blood supply as well as
establishing secondary foci during metastasis.
Conditioned medium from estrogen treated thyroid
cancer cells enhance proliferation of endothelial cells
To examine the growth stimulation of HUVECs in re-
sponse to thyroid cancer cell conditioned medium, we
cultured HUVECs in presence of conditioned medium
collected from thyroid cancer cells for 24 hours. The
number of HUVECs in culture with thyroid cancer cell
conditioned medium from cells treated with estrogen
was significantly higher than that of the untreated thy-
roid cancer cell conditioned media (controls) (Figure 1B).
The increase in proliferation with estrogen treated thy-
roid cancer cell conditioned medium was 33% for B-
CPAP, 31% for CGTH-W-1 and 41% for ML-1. This es-
trogen enhanced cell proliferation was down-regulated
when thyroid cancer cells were treated with fulvestrant
along with estrogen. These experiments suggest that pro-
liferation of HUVECs is associated with mitogenic sol-
uble factor(s) secreted by thyroid cancer cells when
treated with estrogen.
Enhanced tubulogenesis of HUVECs is induced by
conditioned media from estrogen treated thyroid cancer
cells
To investigate the pro-angiogenic effects of estrogen in
TPD with respect to this tubular network formation, an
in vitro tubulogenesis assay was performed using
HUVECs (Figure 1C). HUVECs were cultured on the
Matrigel coated plates in the presence of conditioned
medium collected from thyroid cancer cells treated with
estrogen ± fulvestrant for the period of four hours.
MatrigelTM is a basement membrane matrix containing
collagen, fibronectin and laminin and it mimics an
in vivo basement membrane [22]. Culturing HUVECs on
this substrate allowed us to observe how the endothelial
cells behave in response to the tumor cells secreted
B-CPAP 
M L-1 
Figure 1 Estrogen treated thyroid cancer cells enhance angiogenesis of HUVECs. (A) Estrogen treated thyroid cancer cells enhance HUVEC
migration. Conditioned medium from thyroid cancer cells with 10-8 M E2 ± 10
-6 M fulvestrant was used as chemoattractant for HUVECs. The
HUVECs that migrated and adhered on the lower surface of the membrane were fixed, stained, and counted in 10X field. The groups are as
follows- HUVECs migrated to the untreated (black bars), E2 treated (grey bars) and E2 and fulvestrant treated (white bars) conditioned medium.
Data expressed as numbers of HUVECs counted (migrated cells) per 10X field micrograph for each sample well and normalized to the untreated
control set as 100%. The asterisk denotes statistically significant differences (p< 0.05) between experimental and untreated samples determined
using a paired Student’s t - test. (B) Estrogen treated thyroid cancer cells enhance HUVEC proliferation. HUVECs were cultured in presence of
thyroid cancer cell conditioned medium for 24 hours followed by trypan blue exclusion cell count to calculate endothelial cell proliferation. The
groups are as follows- HUVECs cultured with untreated (black bars), E2 treated (grey bars) and E2 and fulvestrant treated (white bars) conditioned
medium. Data expressed as % of HUVECs cell number normalized to the untreated controls set as 100%. The asterisk denotes statistically
significant differences (p< 0.05) between experimental and untreated samples determined using a paired Student’s t – test. (C) Enhances tube
formation of HUVECs induced by estrogen treated thyroid cancer cell conditioned medium. HUVECs were seeded in B-CPAP and ML-1 thyroid
cancer cell conditioned medium on Growth factor-reduced Matrigel and were monitored for tubulogenesis. The results are representative of three
independent experiments performed in triplicates.
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CPAP and ML-1 thyroid cancer cells treated with estrogen
can stimulate the formation of well defined capillary-like
structures by HUVECs on matrigel, while HUVECs formed
short stumped structures on matrigel when cultured with
estrogen and fulvestrant treated thyroid cancer cell condi-
tioned media. This enhanced tubulogenesis of HUVECs
with estrogen treated thyroid cancer cell conditioned media
was not due to proliferation of HUVECs as the number of
HUVECs was not affected in six hours.Estrogen induces VEGF secretion of thyroid cancer cells
To investigate whether VEGF acts as an effector mol-
ecule for estrogen stimulated angiogenic phenotypic
characteristic of HUVECs, we quantified in vitro VEGF
secretion by B-CPAP (Figure 2A) and ML-1 (Figure 2B)
in response to estrogen and fulvestrant by a quantitative
VEGF-ELISA. Basal in vitro secretion of VEGF (un-
treated) was 6108 pg/ml in B-CPAP and 1103 pg/ml in
ML-1. When treated with estrogen, the thyroid cancer
cells displayed an enhanced VEGF secretion with
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corresponds to a significant increase (50-55%) in VEGF
secretion upon estrogen treatment. With fulvestrant, the
VEGF secretion was reverted back to untreated levels.
These enhanced levels of VEGF potentially increase the
endothelial cells ability to establish neovasculature, as
evidenced by the observed in vitro migration, prolifera-
tion and tubulogenesis of endothelial cells.Blocking secreted VEGF suppresses angiogenesis
associated events in thyroid cancer cells
To further validate the role of VEGF in enhanced angio-
genesis of thyroid cancer cells and understand the mechan-
ism by which estrogen regulates angiogenesis, we
neutralized secreted VEGF in the conditioned medium by
using an anti-human neutralizing VEGF antibody. Free
secreted VEGF can bind to the VEGF-receptor (VEGFR)
present on endothelial cells enabling them to migrate, pro-
liferate and form tubules. By using a neutralizing VEGF
antibody, we blocked this step of angiogenesis. Thyroid can-
cer cells were incubated with estrogen and fulvestrant to
generate conditioned medium, which was evaluated for
VEGF secretion. One microgram of neutralizing VEGF anti-
body was then incubated with the conditioned medium to
neutralize free-VEGF. This conditioned medium was then
subjected to HUVEC migration, proliferation and tubulo-
genesis to confirm the effects of VEGF on thyroid cancer
angiogenesis. Conditioned medium, without neutralizing
antibody, was also used as an internal control. We discov-
ered that in presence of neutralizing antibody, the migration
of HUVECs in response to estrogen treated thyroid cancer
cell conditioned medium was suppressed (Figure 3A). We





























Figure 2 Effect of estrogen on the in vitro VEGF secretion by thyroid
density of 5X105 cells per well in six-well culture dishes and allowed to adh
medium and incubated with ± 10-8 M E2 ± 10
-6 M fulvestrant or left untreate
CPAP and (B) ML-1 conditioned medium was assayed for VEGF secretion us
differences (p< 0.05) between experimental and untreated samples determ
represents n = 3 for each sample.HUVECs with estrogen treated ML-1 conditioned medium,
which was suppressed to only 16-18% when secreted VEGF
was neutralized. The HUVEC proliferation in response to
estrogen treated thyroid cancer cell conditioned medium
was also down-regulated when secreted VEGF was neutra-
lized (Figure 3B). Also, a similar suppression in HUVEC
tubulogenesis was observed with VEGF neutralizing anti-
body (Figure 3C). This further clarified that the induction in
angiogenesis associated events by estrogen is due to
enhanced secretion of VEGF in combination with other
growth factors not currently identified in this study, which
may explain only a partial inhibition in the angiogenesis
associated events in the presence of the neutralizing VEGF
antibody.Dietary compound DIM inhibits estrogen induced
angiogenesis of thyroid cancer cells
To determine whether conditioned medium from DIM
treated thyroid cancer cells could reduce angiogenesis asso-
ciated events in HUVECs, we performed in vitro angiogen-
esis assay of HUVECs. Firstly, as shown in Figure 4A and
additional file 1, HUVECs migration is reduced towards
DIM treated samples compared to untreated samples. More
interestingly, DIM was able to down-regulate the estrogen
induced HUVEC migration (compare grey and striped
bars). Moreover, HUVEC proliferation was suppressed in
the presence of conditioned medium from DIM treated thy-
roid cancer cells. Especially for ML-1, proliferation of
HUVECs was significantly down-regulated for conditioned
medium from DIM and DIM+estrogen treated thyroid
cancer cells (Figure 4B and additional file 1). Furthermore,
tubulogenesis of endothelial cells (HUVECs) was performed




























cancer cells. B-CPAP and ML-1 thyroid cancer cells were seeded at a
ere overnight. Thyroid cancer cells were then switched to serum free
d for 24 hours. The conditioned medium was harvested and (A) B-
ing VEGF ELISA kit. The asterisk denotes statistically significant
ined using a paired Student’s t - test. The standard deviation
Figure 3 HUVEC migration, proliferation and tubulogenesis are suppressed by VEGF neutralizing antibody. Conditioned medium
generated by culturing ML-1 thyroid cancer cells with ± 10-8 M E2 ± 10
-6 M fulvestrant was incubated with 1 μg of anti-human VEGF neutralizing
antibody per mL of the conditioned media at 37°C for one hour. (A) HUVECs were allowed to migrate towards thyroid cancer cell conditioned
medium with or without the VEGF neutralizing antibody used as chemoattractant. Data expressed as numbers of HUVECs counted (migrated cells)
per 10X field micrograph for each sample well and normalized to the untreated control. The asterisk denotes statistically significant differences
(p< 0.05) between experimental and untreated samples determined using a paired Student’s t - test. (B) HUVECs were cultured in presence of
thyroid cancer cell conditioned medium followed by trypan blue exclusion cell count to calculate endothelial cell proliferation. Data expressed as
% of HUVECs cell number normalized to the untreated control (no neutralizing antibody) set as 100%. The asterisk denotes statistically
significant differences (p< 0.05) between experimental and untreated samples determined using a paired Student’s t - test. (C) HUVECs were
seeded in ML-1 thyroid cancer cell conditioned medium with or without the VEGF neutralizing antibody on matrigel and monitored for
tubulogenesis. The results are representative of three independent experiments performed in triplicates.
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formed irregular structures on matrigel when cultured with
DIM-conditioned media with no well defined tubules even
when DIM and estrogen treatments were combined
(Figure 4C). The effect of DIM on estrogen mediated tubu-
logenesis was comparable to activity of fulvestrant, suggest-
ing that DIM possess not only anti-estrogenic activity but
also anti-angiogenic activity as well.
DIM down-regulates estrogen enhanced VEGF secretion
We have recently shown that DIM targets estrogen
enhanced MMP secretion [17] and estrogen enhancesin vitro angiogenesis associated events (current
study), thus to examine the mechanism of action of
DIM as an inhibitor of estrogen enhanced angiogen-
esis, we determined whether DIM inhibited VEGF se-
cretion of thyroid cancer cells. Conditioned medium
from thyroid cancer cells treated with DIM ± estro-
gen was quantified for in vitro VEGF secretion of B-
CPAP and ML-1 (Figure 5A, 5B and additional file
2) in response to estrogen and DIM by VEGF-ELISA.
We discovered that the levels of VEGF were down-
regulated for DIM treated samples, suggesting that
the decreased levels of VEGF in conditioned medium
Figure 4 Estrogen enhanced HUVEC migration, proliferation and tubulogenesis are attenuated by DIM. (A) Conditioned medium was
generated by culturing thyroid cancer cells with 10-8 M E2 ± 25 μM DIM or left untreated for 24 hours. HUVECs were allowed to migrate towards
thyroid cancer cell conditioned medium used as chemoattractant. The HUVECs that migrated and adhered on the lower surface of the membrane
were fixed, stained, and counted in 10X field. The groups are as follows- HUVECs migrated to the untreated (white bars), E2 treated (grey bars), E2
and fulvestrant treated (dotted bars), 25 μM DIM (black bars) and 25 μM DIM+ E2 conditioned medium (striped bars). Data expressed as numbers
of HUVECs counted (migrated cells) per 10X field micrograph for each sample well and normalized to the untreated control. (B) HUVECs were
cultured in presence of thyroid cancer cell conditioned medium followed by trypan blue exclusion cell count to calculate endothelial cell
proliferation. The groups are as follows- HUVECs migrated to the untreated (white bars), E2 treated (grey bars), E2 and fulvestrant treated (dotted
bars), 25 μM DIM (black bars) and 25 μM DIM+ E2 conditioned medium (striped bars). Data expressed as % of HUVECs cell number normalized to
the untreated control. The asterisk denotes statistically significant differences (p< 0.05) between experimental and untreated group using one
way ANOVA tests. (C) Conditioned medium was generated by culturing ML-1 cells with estrogen ± DIM for 24 hours. Growth factor-reduced
Matrigel was plated and allowed to polymerize in 96-well plates. HUVECs were seeded in ML-1 thyroid cancer cell conditioned medium on
matrigel. The plate was incubated for four to six hours and the wells were photographed using an inverted microscope with a digital camera. The
results are representative of three independent experiments performed in triplicates.
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sible for reduced angiogenesis of HUVECs.
DIM modulates VEGF expression in HUVECs
To further explore the ability of DIM to disrupt
angiogenesis, we treated HUVECs with thyroid can-
cer cell conditioned medium for 24 hours, followed
by Western blot analysis of whole HUVEC cell
lysates (Figure 6). We found that DIM successfullyinhibits the expression of VEGF in HUVECs when
thyroid cells were treated with DIM, which may be
due to reduced levels of VEGF and other growth fac-
tors released by thyroid cancer cells in conditioned
medium when treated with DIM. These reduced
levels of mitogenic factors potentially weaken the
ability of endothelial cells to establish vascularization.
Our data suggests a strong link between estrogen





























































Figure 5 DIM targets VEGF secretion of thyroid cancer cells. B-CPAP and ML-1 thyroid cancer cells were seeded at a density of 5×105
cells per well in six-well culture dishes and allowed to adhere overnight. Thyroid cancer cells were then switched to serum free medium
and incubated with ± 10-8 M E2 ± 10
-6 M fulvestrant or left untreated for 24 hours. The conditioned medium was harvested and (A) ML-1 and (B)
B-CPAP VEGF was assayed using VEGF ELISA kit. The asterisk denotes statistically significant differences (p< 0.05) between the treatment and
untreated samples determined using a one way ANOVA test. The standard deviation represents n = 3 for each sample.
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DIM, to inhibit any direct effect of estrogen on thy-
roid cells thus allowing the possible development of
an anti-estrogenic therapy for thyroid malignancies.
Discussion
Certain conditions such as inflammation, hypoxia and
genetic lesions are known to modulate the angiogenic
switch which comprises of a balance between positive
and negative regulators [23-25]. We have earlier demon-
strated that estrogen is a promoter of thyroid cancer. In
this study, we provided evidences that the higher inci-
dence of thyroid cancer in females is potentially attribu-
ted to the presence of a functional ER that participates
in cellular processes contributing to enhanced mitogenic
and metastatic properties of thyroid cells [26]. We have
also demonstrated that DIM targets estradiol inducedthyroid cancer cell proliferation and metastasis asso-
ciated events, namely adhesion, migration and invasion,
potentially by targeting the metastatic modulators MMP-
2/MMP-9 [17], that not only regulate angiogenesis but
are also required for degradation of collagen, a major
component of extracellular matrices [27,28]. MMPs have
also shown to enhance the bioavailability of VEGF by
proteolytically cleaving the extracellular matrix bound
VEGF allowing the association between VEGF and its re-
spective receptor, VEGFR [28-31]. This association be-
tween growth factor and its respective receptor aids in
the generation of tumor microenvironment which is con-
ducive to tumor growth and angiogenesis [28,30,31].
These observations suggest the potential role of estrogen
in mediating angiogenesis of thyroid cancer cells.
We provide evidence in this report that estrogen treat-
ment leads to enhanced levels of VEGF secretion by
VEGF 
Actin 
Figure 6 DIM down-regulates estrogen enhanced VEGF
expression of HUVECs. ML-1 thyroid cancer cells were seeded
at a density of 5×105 cells per well in six-well culture dishes
and allowed to adhere overnight. Thyroid cancer cells were then
switched to serum free medium and incubated with ± E2 ±DIM or
left untreated for 24 hours. The conditioned medium was harvested
and HUVECs were cultured in presence of this conditioned medium
for 24 hours, followed by whole cell lysate formation. Subsequently,
Western blot analysis was performed using anti-VEGF antibody to
analyze VEGF expression in HUVECs.
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esis associated events, including migration, proliferation
and tubulogenesis of endothelial cells cultured in pres-
ence of thyroid cancer cell conditioned medium. We dis-
covered that thyroid cancer cells and endothelial cells
crosstalk via growth factors such as VEGF. Many studies
demonstrate that VEGF plays a central and critical role
in angiogenesis, regulating the expression of angiogenesis
related genes in endothelial cells and the proliferation,
migration as well as tubulogenesis of endothelial cells
[6,7,9,12,15]. These studies demonstrating the contribu-
tion of VEGF were validated in the presence of VEGF
neutralizing antibody.
We further evaluated the effects of DIM on angio-
genesis of thyroid cancer. Therapeutic and preventive
strategies that target VEGF such as anti-VEGF anti-
bodies and soluble VEGF receptors have been shown
to reduce growth of several cancers but thyroid. We
present in the current report that the estrogen
induced angiogenesis is targeted by anti-estrogen
DIM by downregulating the bioavailability of proan-
giogenic factor VEGF as evidenced by reduced angio-
genesis of HUVEC by DIM treated thyroid cancer
cell conditioned medium. The ability of an anti-es-
trogen to inhibit any direct effect of estrogen on thy-
roid cancer cells suggests that the estrogen receptor
is a viable target for treatment of thyroid cancer by
way of using anti-estrogens in therapeutic and pre-
ventive settings. This was potentially due to reduced
levels of secreted VEGF with anti-estrogen treatments.These reduced levels of mitogenic factors such as VEGF, po-
tentially weaken the ability of endothelial cells to establish
structures essential to vascularization of tissues, suggesting
the usefulness of anti-estrogens such as DIM for treatment
against aggressive thyroid carcinomas. The anti-angiogenic
effects of DIM on estrogen induced migration, proliferation
and tubulogenesis of endothelial cells, which leads to
reduced angiogenesis shows a strong potential for use of
DIM in thyroid cancer treatment and has been identified as
a potential antitumor therapies candidate. Further in vivo
experiments for the usefulness of DIM in controlling the
angiogenesis of thyroid tumor are underway by our group.Conclusion
In its entirety, the results from the current study suggest
a strong link between estrogen and angiogenesis of thy-
roid cancer as evidenced by in vitro observations. Con-
sidering that thyroid vascularization is seminal for
pathogenesis of thyroid proliferative disease, our findings
may have clinical utility in targeting endothelial cells for
antitumor therapies, thus disrupting tumor vasculogen-
esis and aggressive thyroid tumors. Our results demon-
strate the primary role of estradiol in modulating
discrete events of angiogenesis in thyroid cells and that
all of these cells have the propensity to be estrogen
modulated. Our cell culture model using thyroid epithe-
lial cancer cells and endothelial cells establish a cell-cell
interactive system that highlights the role of estrogen in
cancer progression. It delineates an important epidemio-
logical observation at the cellular tumor microenviron-
ment level. Combinational therapies that employ anti-
angiogenic and anti-estrogenic agents, such as DIM and
anti-VEGF, used in this study, are viable treatment and
preventive strategies and are a model for the translation
of in vitro molecular target based identification that can
affect clinical practice.Additional files
Additional file 1: Figure S1 Fulvestrant does not affect HUVEC
migration and proliferation. (A) Conditioned medium was generated by
culturing thyroid cancer cells with 10-8 M E2 ± 25 μM DIM± 10
-6 M
Fulvestrant or left untreated for 24 hours. HUVECs were allowed to
migrate towards thyroid cancer cell conditioned medium used as
chemoattractant. The HUVECs that migrated and adhered on the lower
surface of the membrane were fixed, stained, and counted in 10X field.
The groups are as follows- HUVECs migrated to the untreated (white
bars), E2 treated (grey bars), E2 and fulvestrant treated (dotted bars),
25 μM DIM (black bars), 25 μM DIM+ E2 conditioned medium (striped
bars) and fulvestrant treated (light gray bars). Data expressed as numbers
of HUVECs counted (migrated cells) per 10X field micrograph for each
sample well and normalized to the untreated control. (B) HUVECs were
cultured in presence of thyroid cancer cell conditioned medium followed
by trypan blue exclusion cell count to calculate endothelial cell
proliferation. The groups are as follows- HUVECs migrated to the
untreated (white bars), E2 treated (grey bars), E2 and fulvestrant treated
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http://www.translational-medicine.com/content/10/1/81(dotted bars), 25 μM DIM (black bars), 25 μM DIM+ E2 conditioned
medium (striped bars) and fulvestrant treated (light gray bars). Data
expressed as % of HUVECs cell number normalized to the untreated
control. The asterisk denotes statistically significant differences (p< 0.05)
between experimental and untreated group using one way ANOVA tests
Additional file 2: Figure S2 Fulvestrant does not affect VEGF secretion
of thyroid cancer cells. B-CPAP and ML-1 thyroid cancer cells were
seeded at a density of 5X105 cells per well in six-well culture dishes and
allowed to adhere overnight. Thyroid cancer cells were then switched to
serum free medium and incubated with ± 10-8 M E2 ± 10
-6 M fulvestrant
or left untreated for 24 hours. The conditioned medium was harvested
and (A) ML-1 and (B) B-CPAP VEGF was assayed using VEGF ELISA kit. The
asterisk denotes statistically significant differences (p< 0.05) between the
treatment and untreated samples determined using a one way ANOVA
test. The standard deviation represents n = 3 for each sample
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